Molecular Diagnostic Test Identifies Patients Likely to Benefit from Hypnosis for Pain Relief

Listen to this News

Highlights:

• The GMR biosensor array can detect the ideal mix of COMT SNPs in patient DNA samples, providing a quick and objective way to identify patients who are likely to benefit from hypnotherapy for pain relief
• The study found that the association between hypnotizability and COMT genotypes was strongest in females, possibly due to interactions between COMT and estrogen. Further research may focus on other gene targets, including COMT, with stratification by sex
• The study emphasizes the potential of evolving precision medicine applications to identify patients who are most likely to benefit from hypnosis as an effective, non-pharmacological treatment that can improve patient comfort while reducing opioid use

For many people, hypnosis is an excellent pain treatment, but predicting which patients will benefit the most can be difficult. Hypnotizability testing necessitates specialized expertise and in-person evaluation, both of which are uncommon in the therapeutic arena. Researchers have now created a quick, point-of-care molecular diagnostic test that identifies a subset of people who are most likely to benefit from hypnotherapy therapies for pain relief. Their study, published in Elsevier's The Journal of Molecular Diagnostics, also discovered that a subpopulation of highly hypnotizable patients may be more likely to experience significant levels of postoperative pain.

Treatments for Pain Management

"Since hypnotizability is a stable cognitive trait with a genetic basis, our goal was to create a molecular diagnostic tool for objectively identifying individuals who would benefit from hypnosis by determining �treatability' at the point-of-care," explained co-lead investigator Dana L. Cortade, a recently graduated Ph.D. in Materials Science and Engineering, School of Engineering, Stanford University, Stanford, CA, USA. "The advancement of nonpharmacological adjuvant treatments for pain is of the utmost importance in light of the opioid epidemic."

A previous study demonstrated that the genetic foundation for hypnotizability contains four unique single-nucleotide polymorphisms (SNPs), or genetic variants, found in the catechol-o-methyltransferase (COMT) gene, which is important for dopamine metabolism in the prefrontal cortex. Although SNPs can provide useful information about disease risk and treatment response, their general use in clinical practice is limited due to the difficulties, costs, and time delays associated with shipping samples to laboratories for testing.

‘Researchers have developed a molecular diagnostic test using a GMR biosensor array that can quickly identify patients who are likely to benefit from hypnotherapy for pain relief. The test detects the ideal mix of COMT single-nucleotide polymorphisms (SNPs) in patient DNA samples, which are associated with hypnotizability and pain sensitivity.’

To detect the ideal mix of COMT SNPs in patient DNA samples, the researchers built an SNP genotyping assay on a large magnetoresistive (GMR) biosensor array. GMR biosensor arrays are dependable, inexpensive, sensitive, and simple to use in point-of-care settings with saliva or blood samples.

The study looked at the relationship between COMT diplotypes and hypnotizability using a clinical hypnotizability scale called the Hypnotic Induction Profile (HIP) in people who had taken part in one of three previous clinical trials that used a HIP. For patients from the third cohort who had undergone total knee arthroplasty, an additional exploratory examination of the relationship between perioperative pain, COMT genotypes, and HIP scores was conducted (TKA). DNA was extracted from blood samples provided in the first cohort, and saliva samples were acquired from participants in the other two trials via mail. Individuals with HIP scores of 3 or higher on a scale of zero to ten were judged curable by hypnosis.

The GMR biosensor array detected the optimum COMT diplotypes in 89.5% of the subjects, identifying 40.5% of the curable group. The mean HIP score in the optimal COMT group was considerably greater than that in the subpar COMT group. However, subsequent investigation revealed that the difference was exclusively observed in women.

Gender Disparity in the Association Between Hypnosis and Genotypes

"Although we had expected some difference in effect between females and males, the association between hypnotizability and COMT genotypes was strongest in the females in the cohort," said co-lead investigator Jessie Markovits, M.D., Department of Internal Medicine, Stanford School of Medicine, Stanford, CA, USA. "The difference may be due to lower numbers of males in the cohort, or because COMT is known to have interactions with estrogen and to differ in activity by sex. Additional gene targets including COMT, with stratification by sex, could be the focus of future study."

The same ideal COMT individuals had significantly higher postoperative pain scores than the sub par group in the exploratory study of the link between COMT genotypes and pain following TKA surgery, indicating a greater need for treatment. "This reinforces the body of data showing COMT genotypes impact pain, and it is also known that COMT genotypes alter opioid use following surgery. "Pain researchers can utilize this technology to correlate genetic propensity to pain sensitivity and opioid usage with response to an evidence-based, alternative treatment: hypnosis," stated Dr. Cortade.

COMT SNPs alone are not a complete biomarker for identifying all persons who are highly hypnotizable and have high pain sensitivity. The GMR sensor nanoarray may hold up to 80 SNPs, and more SNPs, such as those for dopamine receptors, may be required to further stratify individuals.

Use of Hypnosis in Precision Medicine

The researchers note that this study emphasizes the value and potential of evolving precision medicine applications. "It is a step towards enabling researchers and healthcare professionals to identify a subset of patients who are most likely to benefit from hypnotic analgesia," Dr. Markovits said. "Precision medicine has made great strides in identifying differences in drug metabolism that can impact medication decisions for perioperative pain. We hope to provide similar precision in offering hypnosis as an effective, non-pharmacological treatment that can improve patient comfort while reducing opioid use."

Source: Medindia

Cite this Article ⇣⇡

Please use one of the following formats to cite this article in your essay, paper or report:

• APA

  Dr. Trupti Shirole. (2023, March 21). Molecular Diagnostic Test Identifies Patients Likely to Benefit from Hypnosis for Pain Relief. Medindia. Retrieved on Dec 27, 2024 from https://www.medindia.net/news/healthwatch/molecular-diagnostic-test-identifies-patients-likely-to-benefit-from-hypnosis-for-pain-relief-211000-1.htm.

• MLA

  Dr. Trupti Shirole. "Molecular Diagnostic Test Identifies Patients Likely to Benefit from Hypnosis for Pain Relief". Medindia. Dec 27, 2024. <https://www.medindia.net/news/healthwatch/molecular-diagnostic-test-identifies-patients-likely-to-benefit-from-hypnosis-for-pain-relief-211000-1.htm>.

• Chicago

  Dr. Trupti Shirole. "Molecular Diagnostic Test Identifies Patients Likely to Benefit from Hypnosis for Pain Relief". Medindia. https://www.medindia.net/news/healthwatch/molecular-diagnostic-test-identifies-patients-likely-to-benefit-from-hypnosis-for-pain-relief-211000-1.htm. (accessed Dec 27, 2024).

• Harvard

  Dr. Trupti Shirole. 2023. Molecular Diagnostic Test Identifies Patients Likely to Benefit from Hypnosis for Pain Relief. Medindia, viewed Dec 27, 2024, https://www.medindia.net/news/healthwatch/molecular-diagnostic-test-identifies-patients-likely-to-benefit-from-hypnosis-for-pain-relief-211000-1.htm.